From Wikipedia, the free encyclopedia
Monoclonal antibody
Enoticumab (REGN421,
INN) is a human
monoclonal
antibody that binds to
DLL4. It acts as an
immunomodulator.
[1]
[2]
[3]
[4]
[5]
References
-
^
World Health Organization (2012).
"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
-
^ Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK (June 2016).
"Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth". Mol. Cancer Ther. 15 (6): 1344–52.
doi:
10.1158/1535-7163.MCT-15-0144.
PMC
4893925.
PMID
27009216.
-
^ Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G (October 2015).
"Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer". Cancer Res. 75 (19): 4086–96.
doi:
10.1158/0008-5472.CAN-14-3773.
PMID
26377940.
-
^ Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A (June 2015).
"A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors". Clin. Cancer Res. 21 (12): 2695–703.
doi:
10.1158/1078-0432.CCR-14-2797.
PMID
25724527.
-
^ Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R (2014).
"Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts". PLOS ONE. 9 (11): e112371.
Bibcode:
2014PLoSO...9k2371M.
doi:
10.1371/journal.pone.0112371.
PMC
4231048.
PMID
25393540.